4/A: KORU Medical Systems: Insider Buys Correction

KORU Medical Systems files an amendment to a Form 4, correcting a price entry for a transaction by CEO Linda M. Tharby.

Summary

• This filing is an amendment (Form 4/A) to a previous Form 4 filing.
• The amendment corrects a typographical error in the original Form 4 regarding the price per share of common stock.
• The corrected price for the transaction on May 15, 2026, is $3.92 per share.
• Linda M. Tharby, Chief Executive Officer and Director, acquired 1,191 shares of common stock at this corrected price.
• Following this transaction, Linda M. Tharby beneficially owns 620,622 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily serving as a procedural correction of a previous report without introducing new material information about the company's performance or strategy.

Positives

• Correction of a filing error demonstrates attention to detail and accuracy in reporting.
• The transaction involved the acquisition of shares by the CEO, which can be viewed positively by investors as a sign of confidence in the company.

Negatives

• The filing is an amendment, indicating an initial error in reporting, which could raise minor concerns about internal controls, though it's a common occurrence.

Future Outlook

No specific future outlook or guidance is provided in this amendment filing, as it solely addresses a correction to a past transaction.

Management Comments

• This Form 4/A amendment filing corrects a typographical error found on the original Form 4 filing in Table I, Box 4, Price. The correct price per share is $3.92.
• The filing of this statement shall not be construed as an admission (a) that the person filing this statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this statement, or (b) that this statement is legally required to be filed by such person.

Industry Context

StockSavvy.ai notes that SEC Form 4 filings are standard for tracking insider transactions. Amendments like this are common and typically address minor errors, such as price discrepancies, without signaling significant operational changes.

Stakeholder Impact

• Shareholders: The correction of a price error in an insider transaction filing is unlikely to have a significant impact on shareholders, as it clarifies existing information rather than introducing new material events.

Key Dates

Keywords

Form 4/A, Insider Transaction, SEC Filing, KORU Medical Systems, KRMD, Stock Ownership, CEO Transaction, Beneficial Ownership